MedPath

A Randomized Controlled Trial for Qing Jin Yi Qi granule in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia(COVID-19)

Not Applicable
Recruiting
Conditions
ovel Coronavirus Pneumonia (COVID-19)
Registration Number
ITMCTR2100004379
Lead Sponsor
Shijiazhuang People's Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1) Conform to the diagnostic criteria of COVID-19(Guidelines for the diagnosis and treatment of coronavirus disease 2020(trial version eighth))Patients who met the discharge standard and had negative neocoronavirus nucleic acid detection after discharge
2) Aged 18-75 years;
3) Having clinical manifestations of respiratory symptoms or fatigue;
4) Patient informed consent.

Exclusion Criteria

1) Patients who have undergone operations that affect lung function, such as lung transplantation, lung resection, lung volume reduction, etc;
2) Dependent on mechanical ventilation to maintain lung function, such as ventilator;
3) Combined with chronic lung diseases that affect lung function, such as severe chronic obstructive pulmonary disease;
4) Patients with heart function related diseases, such as heart failure and pacemaker installation;
5) Severe underlying diseases affecting survival, including uncontrolled heart, kidney, digestive, blood diseases, neuropsychiatric diseases, immune diseases, metabolic diseases, malignant tumors, severe malnutrition, etc;
6) Resting heart rate > 120 / min;
7) Systolic blood pressure > 180mmhg, diastolic blood pressure > 100mmhg;
8) Unstable angina pectoris or myocardial infarction in recent 1 month;
9) Severe obesity (BMI > 30 kg / m2);
10) Allergic constitution, allergic to the drug components involved in the treatment program;
11) Pregnant or lactating women;
12) Disabled people who can't complete the collection of efficacy evaluation indicators;
13) Mental state can not cooperate, suffering from mental illness, no self-control, can not express clearly;
14) Participants in other clinical trials;
15) According to the judgment of the researchers, there will be patients with complications or poor compliance that affect the efficacy and safety evaluation.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
modified Medical Research Council Dyspnea Scale (MMRC);Borg perceived fatigue scale;Visual analogue scale for cough;
Secondary Outcome Measures
NameTimeMethod
6 minutes walking distance;Blood oxygen saturation;Immune inflammation index;Depression Scale (PHQ-9), anxiety scale (GAD-7);Chest CT;TCM syndrome score;
© Copyright 2025. All Rights Reserved by MedPath